Total trials
1,389
Active
202
Phase 3
39
Total enrollment
4,839,831
Pipeline matrix
Showing 40 of 134 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Enavogliflozin | — | — | — | — | — | 2 | |
| Midazolam | — | — | — | — | 6 | ||
| Clopidogrel | — | — | — | — | — | 4 | |
| Anticoagulation group | — | — | — | — | — | 2 | |
| Cerebrolyisin | — | — | — | — | — | 1 | |
| a high dose of statin/ezetimib | — | — | — | — | — | 1 | |
| Ferric derisomaltose | — | — | — | — | — | 1 | |
| enavogliflozin 0.3mg | — | — | — | — | — | 1 | |
| enavogliflozin Placebo | — | — | — | — | — | 1 | |
| Botulinum toxin A | — | — | — | — | — | 1 | |
| Intensive targeting group | — | — | — | — | — | 1 | |
| Conventional therapy group | — | — | — | — | — | 1 | |
| Vemlidy | — | — | — | — | — | 1 | |
| Virreal | — | — | — | — | — | 1 | |
| Clopidogrel mono-therapy | — | — | — | — | — | 1 | |
| Dual-antiplatelet therapy | — | — | — | — | — | 1 | |
| Dapagliflozin or Empagliflozin | — | — | — | — | — | 1 | |
| Low intensity statin | — | — | — | — | — | 1 | |
| Moderate intensity statin | — | — | — | — | — | 1 | |
| Sitagliptin 100 mg | — | — | — | — | — | 1 | |
| Sitagliptin 100 mg + Dapagliflozin 10 mg | — | — | — | — | — | 1 | |
| Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg | — | — | — | — | — | 1 | |
| NOAC monotherapy | — | — | — | — | — | 1 | |
| Dual antithrombotic therapy with NOAC and clopidogrel | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | — | — | — | 1 | |
| Maxigesic IV | — | — | — | — | — | 1 | |
| Zastaprazan | — | — | — | — | — | 1 | |
| Rabeprazole | — | — | — | — | — | 1 | |
| Chonline Alphoscerate | — | — | — | — | — | 1 | |
| Atorvastatin 20mg+Ezetimibe 10mg | — | — | — | — | — | 1 | |
| remimazolam | — | — | — | — | 3 | ||
| Atorvastatin 40mg | — | — | — | — | 3 | ||
| Apixaban | — | — | — | — | 2 | ||
| phenylephrine | — | — | — | — | — | 2 | |
| carbogen with or without phenyleprhine | — | — | — | — | — | 1 | |
| BP lowering drugs | — | — | — | — | — | 1 | |
| BP raising drug | — | — | — | — | — | 1 | |
| celecoxib monotherapy | — | — | — | — | — | 1 | |
| celecoxib and metformin combination | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 4 |
94 more active programs hidden
Next readouts
- 2022-06-30
- 2025-04
- 2025-06
- 2025-06-14
- 2025-06-20
- 2025-06-30
- 2025-07
- 2025-07-01
- 2025-08-16
- 2025-11-02
Top conditions
- Coronary Artery Disease52
- Atrial Fibrillation31
- Gastric Cancer30
- General Anesthesia20
- Breast Cancer15
- Stroke15
- Colorectal Cancer13
- Prostate Cancer12
Frequently asked questions about Yonsei University
- How many clinical trials does Yonsei University have on ClinicalTrials.gov?
- Yonsei University is listed as the lead sponsor on 1,389 clinical trials in ClinicalTrials.gov, 202 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Yonsei University's trials are in Phase 3?
- 39 of Yonsei University's trials are in Phase 3, spread across 134 active drug programs.
- What therapeutic areas does Yonsei University focus on?
- Yonsei University's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Atrial Fibrillation, Gastric Cancer, General Anesthesia, Breast Cancer.
- When are Yonsei University's next clinical trial readouts?
- Yonsei University has 10 upcoming primary-completion readouts tracked here; the soonest is “SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study”, expected around 2022-06-30.